Global Drug Delivery Systems (DDS) Market Report 2021-2027 - Acquisitions and Collaborations to Open An Array of Opportunities for the Market to Flourish
Dublin, July 29, 2021 (GLOBE NEWSWIRE) -- The "Drug Delivery Systems (DDS) Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.
Global drug delivery systems market is expected to reach $158,006.4 million by 2027 growing at a mid single digit CAGR from 2020 to 2027 due to escalating necessity of targeted and controlled drug delivery systems to increase the therapeutic efficiency and safety profile of medications.
The need for efficient biologics delivery systems, requirement of novel drug delivery systems for satisfying the therapeutic variations of elderly and pediatric population, increasing R&D expenditure of innovator pharma or biopharma companies and their cost-efficient patent ever-greening strategy either through incremental innovation or through repurposing of drugs by using novel drug delivery systems, the vast drug delivery technology enhanced product pipeline, the trend of acquisitions and collaboration agreements in the drug delivery system industry and persistently increasing prevalence of infectious and non-infectious diseases in need of better, efficient and safer prophylactics and therapeutics.
The necessity to address the various challenges in delivery needs attributed to the expansion of therapeutic modalities from the primary class of small molecules to the current new generation of therapeutics, namely the highly varied and complex biotherapeutics, the need to overcome the limitations of the free or conventional active therapeutic or prophylactic moiety and to protect them or enable them to overcome the intrinsic harsh biological environment to induce their potential therapeutic or prophylactic effect are boosting the drug delivery systems market growth.
The drug delivery enabling technology, product or service providers market is fragmented with the top players occupying minor share of the market and the remaining major share of the market being occupied by other players. The top five players occupy minor share of the market and the remaining major share of the market is occupied by other players.
The top players in drug delivery enabling technology, product or service providers market are Thermo fisher Scientific Inc. (Patheon) (U.S.), Lonza Group Ltd. (Switzerland), Catalent, Inc. (U.S.), Merck KGaA (Germany), Evonik Industries (Germany), Halozyme Therapeutics Inc. (U.S.), Ligand Pharmaceuticals Incorporated (U.S.), Mitsubishi Chemical Holdings Corporation (Qualicaps CO. Ltd.) (Japan), Fujifilm Holdings Corporation (Japan), ACG (Associated Capsule Group) Worldwide (India) and others.
The drug delivery system enhanced drug product providers market is consolidated with the few pharmaceutical players dominating and occupying major share of the market and the remaining minor share of the market being occupied by other players.
The top five pharmaceutical players occupy majority of the market share and the remaining minority share of the market is occupied by other players.
The top players in drug delivery enhanced product providers market are Johnson and Johnson (U.S.), Gilead Sciences Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Abbvie Inc. (U.S.), Takeda Pharmaceutical Company (Japan), Astellas Pharma (Japan), Biogen (U.S.), Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Amgen Inc. (U.S.), Novartis AG (Switzerland) and others.
The drug delivery system enhanced product providers market is consolidated with the top five pharmaceutical players occupying 60.9% of the market share and the remaining 39.1% of the market being occupied by other players.
The top players in drug delivery enhanced product providers market are Johnson and Johnson (U.S.), Gilead Sciences Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Abbvie Inc. (U.S.), Takeda Pharmaceutical Company (Japan), Astellas Pharma (Japan), Biogen (U.S.), Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Amgen Inc. (U.S.), Novartis AG (Switzerland) and others.
Factors Influencing Market
Drivers and Opportunities
Necessity of Drug Delivery Systems for Enhancing Therapeutic Efficiency and Safety Profile of Drugs
Need for Efficient Biologics Delivery Systems
Increasing Demand for Convenient Drug Dosage Forms for Geriatric and Pediatric Population
Increasing R&D Expenditures of Innovator Companies and the Trend of Patent Portfolio Expansion
Vast Drug Delivery Technology Enhanced Drug Product Pipeline
Acquisitions and Collaborations to Open An Array of Opportunities for the Market to Flourish
Increasing Prevalence of Chronic, Communicable and Autoimmune Diseases
Restraints and Threats
High Cost of Drug Delivery Systems and the Subsequent Drug Products
Adverse Effects of Drug Delivery Systems
Inconsistent and Evolving Global Regulatory Landscape
Inefficiency of Toxicity Testing and Evaluation Studies in Characterizing Novel Drug Delivery Systems
Threat of Therapeutic Medical Devices and Drug Delivery Devices
Major Companies
ACG Worldwide
Catalent Inc.
Evonik Industries AG
Fujifilm Holdings Corporation
Halozyme Therapeutics Inc.
Ligand Pharmaceuticals Incorporated
Lonza Group Ltd.
Merck KGAA
Mitsubhishi Chemical Holdings Corporation
Thermo Fisher Scientific Inc.
Companies Mentioned
ACG (Associated Capsule Group) Worldwide
Acuitas Therapeutics
Adocia
Alteogen Inc.
Altimmune Inc.
Altus Formulation Inc.
Amarin Technologies S.A.
Aptamer Group
Aquestive Therapeutics, Inc.
Arcturus Therapeutics Holdings Inc.
Arecor Ltd. ,
Ascendia Pharmaceuticals
BASF SE
Bharat Biotech
BioLingus AG
Bio-path Holdings Inc.
Biotts S.A.
Biovectra Inc.
Blafar Ltd.
Catalent, Inc.
CD Bioparticles
Celares GmbH
Corium Inc.
CureVac
DelSiTech Ltd
Dendritech Inc.
DiNAQOR AG
EnGeneIC Ltd
EryDel
Erytech PharmaSA
Eurofins
Evonik Industries
Evox Therapeutics Limited
Exelead Inc.
Feldan Therapeutics
Feldan Therapeutics
ForDoz Pharma
FujiFilm Holdings Corporation
Halozyme Therapeutics, Inc.
Hielscher Ultrasonics GmbH
Horiba
Hydromer Inc.
i2O Therapeutics Inc.
ILIAS Biologics Inc.
Innocore Pharmaceuticals
InnoCore Technologies BV
InnoMedica Holding AG
IntelGenx Corp.
Interius Biotherapeutics Inc.
Intract Pharma Ltd
KemPharm, Inc.
Klaria Pharma Holding AB
Koru Life Science Ltd.
LDS Biotech
Ligand Pharmaceuticals Incorporated
Lipidor AB
Lipocure Ltd
Lipomedix Pharmaceuticals
Liposoma BV
Lonza Group Ltd.
Lubrizol Life Science
Luye Life Sciences Group
MagForce AG
Magle Chemoswed AB
MDimune Inc.
Medesis Pharma SA
Merck KGaA
Mersana Therapeutics Inc.
MICELLAE Delivery Systems Inc.
Micropore Technologies
Midatech Pharma
Mitsubishi Chemical Holdings Corporation
Mymetics Corporation
Nanocomposix Inc.
Nextage Therapeutics
Novaliq GmbH
Oakwood Labs
Oramed Pharmaceuticals
Orbis Biosciences Inc.
Osmotica Pharmaceuticals plc
Oz Biosciences
Pacira Biosciences Inc.
Penlan Healthcare Ltd.
Piramal Group
PolyActiva Pty Ltd
Rani Therapeutics, LLC
Rubicon Research Private Limited
Serina Therapeutics, Inc.
Shanghai OMNI Pharmaceutical Technology Co. Ltd
SIRION Biotech
Sirnaomics, Inc.
Skyepharma Production SAS
Starpharma Holdings Limited
T&T Scientific Corporation
Taiwan Liposome Company Ltd.
TALLC Corporation Inc.
Tenaya Therapeutics
TFF Pharmaceuticals, Inc.
Thermo fisher Scientific Inc.
Tyndall Formulation Services, LLC.
Vaxart Inc.
Vect-Horus
ViGeneron GmbH
Vivera Pharmaceuticals Inc.
W. R. Grace & Co.-Con
ZuMac Pharmaceutical Company
For more information about this report visit https://www.researchandmarkets.com/r/ezgghs
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900